Last week, vTv Therapeutics Inc (NASDAQ:VTVT) announced that azeliragon, the company’s RAGE inhibitor in development for Alzheimer’s disease (AD) failed in Part A …
vTv Therapeutics Collapses as Alzheimer’s Disease Drug Missed Primary Endpoint It’s a short and dramatic plunge for vTv Therapeutics Inc (NASDAQ:VTVT). Today, the drug …
